Compare Dyne Therapeutics Inc. Common Stock (DYN) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs MasTec Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.09 (market cap $2.86B), while MasTec Inc trades at $191.9 (market cap $16.55B). The key difference: MasTec Inc is far larger — about 5.8× Dyne Therapeutics Inc. Common Stock's market cap, and Dyne Therapeutics Inc. Common Stock is more actively traded (3,341,579 versus 1,530,865). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and MasTec Inc for 25 Days on average.
| DYN | MTZ | |
|---|---|---|
Market Cap | $2.86B | $16.55B |
Volume | 3,341,579 | 1,530,865 |
Sector | Health | Industrials |
52-Week High | $26.78 | $437.51 |
52-Week Low | $14.60 | $190.08 |
Typical Hold Time | 0 Days | 25 Days |
Enterprise Value | $2.18B | $19.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
MasTec (MTZ) trades at $206.12, down 0.35% on the day, with technical indicators showing bearish momentum below key moving averages. The company reported strong revenue growth from $14.3B in 2025 to $16.1B in 2026, with net income improving to $494M. Recent news highlights MTZ's record $21.4B backlog and positioning in AI infrastructure and power delivery markets, though cash flow volatility and premium valuation pose challenges.
Wall Street maintains strong bullish sentiment with 89% buy ratings and a $403.92 consensus price target, representing 96% upside potential. Key opportunities include infrastructure investment cycles and data center expansion, while risks include execution challenges, communications segment softness, and elevated P/E ratio of 32.8x.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
